TIL

Instil Bio, Inc. is a pioneering clinical-stage biopharmaceutical company headquartered in Dallas, Texas, focusing on cutting-edge cell therapies aimed at transforming cancer treatment. The company is dedicated to the development of its proprietary tumor-infiltrating lymphocyte (TIL) therapies, which are designed to enhance the immune response against various cancer types. With a robust pipeline that emphasizes personalized immunotherapy solutions, Instil Bio is strategically positioned to address significant unmet needs in oncology, with the potential to significantly improve patient outcomes and reshape the landscape of cancer care.